Helio Genomics Unveils Promising Cancer Detection Research at 2025 Digestive Disease Week in San Diego

Helio Genomics Showcases Groundbreaking Cancer Detection Studies

Helio Genomics, an innovative healthcare company driven by artificial intelligence (AI), has presented compelling findings from three pivotal research studies on cancer detection methods at the 2025 Digestive Disease Week, held in San Diego from May 4 to May 6. The company's focus on advancing diagnostics technology marks a significant step toward earlier and more effective cancer detection methods.

Highlights from the Research Presentations

Study 1: Blood Tests vs. Ultrasound for Hepatocellular Carcinoma (HCC)

Presented by Dr. Amit Singal, this study is centered around the effectiveness of HelioLiver Dx, a multi-analyte blood test, compared to the traditional ultrasound method for identifying hepatocellular carcinoma in patients with cirrhosis. Utilizing a Monte Carlo simulation, the study found that the blood test demonstrated a sensitivity rate of up to 100% in detecting any-stage HCC within 18 months. Particularly noteworthy is its ability to identify early-stage HCC with sensitivities of 61.2% at the same time frame.

Dr. Singal commented, “This simulation study underscores the potential of multi-analyte blood-based tests as a viable alternative to ultrasound, especially for detecting smaller tumors that could benefit from curative treatments.” These findings advocate for a shift in how healthcare providers may approach cancer screenings, particularly for high-risk patients.

Study 2: Methylation Biomarkers for Prognosis and Treatment Response

The second study, led by Shivani Mahajan, Ph.D., focused on using cell-free DNA methylation biomarkers for evaluating the prognosis and treatment responses in hepatocellular carcinoma patients. This research outlines how these biomarkers could revolutionize the way healthcare providers assess disease progression and patient responses to therapies. The insights gained here could lead to improved personalized medicine approaches in managing liver cancer.

Study 3: The CLiMB Study

The third study, conducted by Dr. Richard Van Etten, evaluated the results of the CLiMB study—one of the largest prospective trials assessing a blood-based test's effectiveness in detecting HCC in patients with liver cirrhosis. The findings further elucidate the clinical viability and reliability of using a multi-analyte blood test for early detection, reinforcing Helio Genomics' position as a leader in this emerging field.